Salmonella enterica serovar Typhimurium strain lacking pmrG-HM-D provides excellent protection against salmonellosis in murine typhoid model

Vaccine

Volumn 25, Issue 29, 2007, Pages 5315-5323

  Negi, Vidya Devi ^a   Singhamahapatra, Santanu ^a   Chakravortty, Dipshikha ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

pmrG HM D mutant; Salmonella tyhpimurium; Vaccine

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; LIVE VACCINE; PMRG HM D VACCINE; POLYPEPTIDE ANTIBIOTIC AGENT; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE LOCUS; IMMUNITY; MORTALITY; MOUSE; MUTANT; NONHUMAN; PMRG HM D GENE; PRIORITY JOURNAL; SALMONELLA ENTERICA; SALMONELLA TYPHIMURIUM; SALMONELLOSIS; SEROTYPE; SINGLE DRUG DOSE; SITE DIRECTED MUTAGENESIS; TYPHOID FEVER; WILD TYPE;

ANIMALS; BACTERIAL PROTEINS; BACTERIAL VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FEMALE; IMMUNIZATION, SECONDARY; LIVER; LYMPH NODES; MICE; MICE, INBRED BALB C; MUTAGENESIS, SITE-DIRECTED; PEYER'S PATCHES; PREGNANCY; SALMONELLA TYPHIMURIUM; SPLEEN; SURVIVAL ANALYSIS; T-LYMPHOCYTE SUBSETS; TYPHOID FEVER; TYPHOID-PARATYPHOID VACCINES; VACCINES, ATTENUATED;

EID: 34250827800     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.05.015     Document Type: Article

References (20)

1. Synder JW, Check W. Bioterrorism threats to our future. A report from American Society of Microbiology; 2000.
2. Crump J.A., Luby S.P., and Mintz E.D. The global burden of typhoid fever. Bull World Health Organ 82 (2004) 346-353
3. Bhan M.K., Bahl R., and Bhatnagar S. Typhoid and paratyphoid fever. Lancet 366 (2005) 749-762
4. Kirkpatrick B.D., McKenzie R., O'Neill J.P., et al. Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers. Vaccine 24 (2006) 116-123
5. Khan S.A., Stratford R., Wu T., et al. Salmonella typhi and S typhimurium derivatives harbouring deletions in aromatic biosynthesis and Salmonella Pathogenicity Island-2 (SPI-2) genes as vaccines and vectors. Vaccine 21 (2003) 538-548
6. Tacket C.O., Sztein M.B., Losonsky G.A., Wasserman S.S., Nataro J.P., Edelman R., et al. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. Infect Immun 65 (1997) 452-456
7. Ivanoff B, Levine MM, Lambert PH. Vaccination against typhoid fever: present status. Bull WHO 1994;72:957.26.
8. Miller S.I., Loomis W.P., Alpuche-Aranda C., Behlau I., and Hohmann E. The PhoP virulence regulon and live oral Salmonella vaccines. Vaccine 11 2 (1993) 122-125
9. Yrlid U., Svensson M., Hakansson A., Chambers B.J., Ljunggren H.G., and Wick M.J. In vivo activation of dendritic cells and T cells during Salmonella enterica serovar Typhimurium infection. Infect Immun 69 (2001) 5726-5735
10. Sebastiani G., Blais V., Sancho V., Vogel S.N., Stevenson M.M., Gros P., et al. Host immune response to Salmonella enterica serovar Typhimurium infection in mice derived from wild strains. Infect Immun 70 (2002) 1997-2009
11. Trezena A.G., Souza C.M., Borrego A., Massa S., Siqueira M., De Franco M., et al. Co-localization of quantitative trait loci regulating resistance to Salmonella typhimurium infection and specific antibody production phenotypes. Microbes Infect 4 (2002) 1409-1415
12. Eguchi Y., and Utsumi R. A novel mechanism for connecting bacterial two-component signal-transduction systems. Trends Biochem Sci 30 (2005) 70-72
13. Datsenko K.A., and Wanner B.L. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci USA 97 June (12) (2000) 6640-6645
14. Huang D.B., and DuPont H.L. Problem pathogens: extra-intestinal complications of Salmonella enterica serotype Typhi infection. Lancet Infect Dis 5 (2005) 341-348
15. DeRoeck D., Clemens J.D., Nyamete A., and Mahoney R.T. Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia. Vaccine 23 (2005) 2762-2774
16. Gunn J.S., Ryan S.S., Van Velkinburgh J.C., Ernst R.K., and Miller S.I. Genetic and functional analysis of a PmrA-PmrB-regulated locus necessary for lipopolysaccharide modification, antimicrobial peptide resistance, and oral virulence of Salmonella enterica serovar Typhimurium. Infect Immun 68 (2000) 6139-6146
17. Nishino K., Hsu F.F., Turk J., Cromie M.J., Wosten M.M., and Groisman E.A. Identification of the lipopolysaccharide modifications controlled by the Salmonella PmrA/PmrB system mediating resistance to Fe(III) and Al(III). Mol Microbiol 61 (2006) 645-654
18. Nagy G., Dobrindt U., Hacker J., and Emody L. Oral immunization with an rfaH mutant elicits protection against salmonellosis in mice. Infect Immun 72 (2004) 4297-4301
19. Tang I.K., Ji D.D., Chou C.F., Lin H.C., Liao C.L., Sytwu H.K., et al. Characterization of a highly attenuated Salmonella enterica serovar Typhimurium mutant strain. J Microbiol Immunol Infect 35 (2002) 229-235
20. Valentine P.J., Devore B.P., and Heffron F. Identification of three highly attenuated Salmonella typhimurium mutants that are more immunogenic and protective in mice than a prototypical aroA mutant. Infect Immun 66 (1998) 3378-3383